| Literature DB >> 31717688 |
Bartosz Wojciuk1, Agata Salabura2, Bartłomiej Grygorcewicz3, Karolina Kędzierska2, Kazimierz Ciechanowski2, Barbara Dołęgowska3.
Abstract
The human microbiome has been proven to contribute to the human condition, both in health and in disease. The metagenomic approach based on next-generation sequencing has challenged the dogma of urine sterility. The human urobiome consists of bacteria and eukaryotic viruses as well as bacteriophages, which potentially represent the key factor. There have been several significant findings with respect to the urobiome in the context of urological disorders. Still, the research on the urobiome in chronic kidney disease and kidney transplantation remains underrepresented, as does research on the role of the virome in the urinary microbiota. In this review, we present recent findings on the urobiome with a particular emphasis on chronic kidney disease and post-kidney transplantation status. Challenges and opportunities arising from the research on the human urobiome will also be discussed.Entities:
Keywords: chronic kidney disease; urobiome; virome
Year: 2019 PMID: 31717688 PMCID: PMC6921077 DOI: 10.3390/microorganisms7110548
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Urobiome differentiation in healthy individuals according to gender and age. 1 Based on 16S ribosomal subunit gene next generation sequencing; 2 based on pyrosequencing.
| Gender | Overall 1 | Age 20–49 2 | Age 50–69 2 | Age > 70 2 |
|---|---|---|---|---|
| Female |
|
|
|
|
| Male |
|
|
| |
Urobiomes in different stages of chronic kidney disease (CKD). IFTA: interstitial fibrosis/tubular atrophy.
| Clinical Status | Microorganisms | Methods |
|---|---|---|
| CKD stage 3–5 |
| V4 region 16s RNA gene sequencing |
| Kidney recipients before transplantation |
| V1–V3 region 16s RNA gene sequencing |
| Males 1 month post transplant—stable function vs. healthy controls |
| V2,3,4,6,7,8,9 region 16s RNA gene sequencing |
| Males 1 month post transplant—IFTA vs. stable function |
| V2,3,4,6,7,8,9 region 16s RNA gene sequencing |
| Females 1 month post transplant—stable function vs. healthy controls |
| V2,3,4,6,7,8,9 region 16s RNA gene sequencing |
| Females 1 month post transplant—IFTA vs. stable function |
| V2,3,4,6,7,8,9 region 16s RNA gene sequencing |
| Males 6 months post transplant—stable function vs. healthy controls |
| V2,3,4,6,7,8,9 region 16s RNA gene sequencing |
| Males 6 months post transplant—IFTA vs. stable function |
| V2,3,4,6,7,8,9 region 16s RNA gene sequencing |
| Females 6 months post transplant—stable function vs. healthy controls |
| V2,3,4,6,7,8,9 region 16s RNA gene sequencing |
| Females 6 months post transplant—IFTA vs. stable function |
| V2,3,4,6,7,8,9 region 16s RNA gene sequencing |
| Kidney recipients first 12 months post transplant vs. healthy controls |
| Shotgun sequencing |
| Kidney recipients with decreased graft function at least 12 months post transplant vs. controls with stable graft function |
| V4, ITS1, ITS2 regions 16s RNA gene fragment sequencing |